BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Purchased by Public Employees Retirement Association of Colorado

Public Employees Retirement Association of Colorado boosted its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRNFree Report) by 5,430.4% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 22,011 shares of the biotechnology company’s stock after acquiring an additional 21,613 shares during the period. Public Employees Retirement Association of Colorado’s holdings in BioMarin Pharmaceutical were worth $2,122,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of BMRN. Amalgamated Bank raised its position in shares of BioMarin Pharmaceutical by 13.4% during the 3rd quarter. Amalgamated Bank now owns 20,667 shares of the biotechnology company’s stock worth $1,829,000 after acquiring an additional 2,439 shares in the last quarter. Atria Wealth Solutions Inc. raised its holdings in BioMarin Pharmaceutical by 5.1% during the third quarter. Atria Wealth Solutions Inc. now owns 9,576 shares of the biotechnology company’s stock worth $847,000 after purchasing an additional 461 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of BioMarin Pharmaceutical by 2.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,304,797 shares of the biotechnology company’s stock worth $115,448,000 after buying an additional 33,592 shares during the last quarter. Shell Asset Management Co. boosted its holdings in shares of BioMarin Pharmaceutical by 10.0% in the 3rd quarter. Shell Asset Management Co. now owns 3,847 shares of the biotechnology company’s stock valued at $340,000 after buying an additional 351 shares in the last quarter. Finally, Pathstone Family Office LLC purchased a new position in shares of BioMarin Pharmaceutical in the 3rd quarter valued at $290,000. 98.71% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other BioMarin Pharmaceutical news, CAO Erin Burkhart sold 2,286 shares of the stock in a transaction on Wednesday, April 10th. The stock was sold at an average price of $90.00, for a total transaction of $205,740.00. Following the sale, the chief accounting officer now owns 16,156 shares in the company, valued at approximately $1,454,040. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other BioMarin Pharmaceutical news, CFO Brian Mueller sold 5,000 shares of the company’s stock in a transaction dated Thursday, May 30th. The shares were sold at an average price of $75.19, for a total value of $375,950.00. Following the transaction, the chief financial officer now directly owns 72,159 shares in the company, valued at approximately $5,425,635.21. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CAO Erin Burkhart sold 2,286 shares of BioMarin Pharmaceutical stock in a transaction dated Wednesday, April 10th. The stock was sold at an average price of $90.00, for a total transaction of $205,740.00. Following the sale, the chief accounting officer now owns 16,156 shares of the company’s stock, valued at $1,454,040. The disclosure for this sale can be found here. Insiders sold 114,588 shares of company stock worth $9,413,633 in the last ninety days. Insiders own 1.85% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have commented on the company. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $110.00 price target on shares of BioMarin Pharmaceutical in a research report on Thursday, April 25th. Morgan Stanley dropped their price target on BioMarin Pharmaceutical from $115.00 to $112.00 and set an “overweight” rating on the stock in a research report on Friday, April 26th. Citigroup decreased their price objective on BioMarin Pharmaceutical from $94.00 to $91.00 and set a “neutral” rating for the company in a research report on Thursday, April 25th. Scotiabank boosted their target price on BioMarin Pharmaceutical from $83.00 to $85.00 and gave the company a “sector perform” rating in a report on Thursday, April 25th. Finally, Evercore ISI began coverage on BioMarin Pharmaceutical in a report on Tuesday, May 14th. They set an “outperform” rating and a $113.00 price target for the company. Nine investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Based on data from MarketBeat, BioMarin Pharmaceutical currently has a consensus rating of “Moderate Buy” and a consensus price target of $106.11.

Read Our Latest Analysis on BioMarin Pharmaceutical

BioMarin Pharmaceutical Stock Down 0.2 %

BioMarin Pharmaceutical stock opened at $80.69 on Monday. BioMarin Pharmaceutical Inc. has a fifty-two week low of $73.68 and a fifty-two week high of $99.56. The firm has a market capitalization of $15.32 billion, a price-to-earnings ratio of 75.41, a price-to-earnings-growth ratio of 1.15 and a beta of 0.31. The stock’s fifty day moving average is $82.85 and its two-hundred day moving average is $88.09. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.70 and a current ratio of 2.74.

BioMarin Pharmaceutical (NASDAQ:BMRNGet Free Report) last issued its quarterly earnings data on Wednesday, April 24th. The biotechnology company reported $0.49 EPS for the quarter, beating analysts’ consensus estimates of $0.37 by $0.12. The firm had revenue of $648.83 million for the quarter, compared to analysts’ expectations of $649.75 million. BioMarin Pharmaceutical had a net margin of 8.31% and a return on equity of 5.34%. Analysts predict that BioMarin Pharmaceutical Inc. will post 1.99 EPS for the current fiscal year.

BioMarin Pharmaceutical Profile

(Free Report)

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.

Featured Stories

Institutional Ownership by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.